Drug Approval | August 12, 2021
Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
The company is eligible for 12 months exclusivity from launch
The company is eligible for 12 months exclusivity from launch
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
As per the Department of Pharmaceuticals, the sector has expanded its reach across the country while strengthening domestic production capabilities and innovation
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
